Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 18/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31619130 | 0.72 | AHR (0.42) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL5320283 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL5337159 | 0.68 | CA12 (0.42) | MAP2K1PARP1 | |
| SCHEMBL25209666 | 0.67 | CDC7 (0.47) | MAP2K1 | |
| SCHEMBL31622808 | 0.67 | POLB (0.44) | MAP2K1 | |
| SCHEMBL980230 | 0.67 | MAP2K1 (0.58) | MAP2K1PARP1 | |
| SCHEMBL5393650 | 0.66 | GSK3B (0.48) | CASP3CASP7CASP6CASP8MAP2K1 | |
| SCHEMBL422023 | 0.64 | TDP2 (1.00) | TDP2CASP3CASP7CASP9CASP6 | |
| Hydrochloric Acid SCHEMBL7001639 | 0.62 | TDP2 (0.96) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL7010445 | 0.62 | MAP2K1 (0.32) | MAP2K1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190317040-A1 | DEVICES AND METHODS FOR TARGET MOLECULE CHARACTERIZATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-17 | — | — | US | disclosed |
| US-10330632-B2 | Devices and methods for target molecule characterization | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170003245-A1 | DEVICES AND METHODS FOR TARGET MOLECULE CHARACTERIZATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-01-05 | — | — | US | disclosed |
| US-9395352-B2 | Devices and methods for target molecule characterization | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-07-19 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100084276-A1 | Devices and Methods for Target Molecule Characterization | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-08 | — | — | US | disclosed |
| WO-2008124706-A9 | DEVICES AND METHODS FOR TARGET MOLECULE CHARACTERIZATION | UNIV ARIZONA STATE (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1228063-B1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORP (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008124706-A2 | DEVICES AND METHODS FOR TARGET MOLECULE CHARACTERIZATION | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007118602-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | TDP2 2446/4885CASP3 1192/4885CASP7 733/4885 |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | PTGIR, PTGIS, EDNRB | TDP2 3673/4885CASP3 3099/4885CASP7 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.